Winhealth is a China-based, Asia Pacific centric, innovative biotechnology company, providing novel breakthrough therapies to patients with rare diseases and other unmet medical needs. The company is headquartered in Hong Kong, with operating hubs in Hangzhou, Shanghai, and Beijing. The company owns China's first rare disease managed access platform in Bo'ao, Hainan. The company also has representative offices in Japan, Singapore and Europe. Winhealth also has a strategic stake in the Cumberland Emerging Technologies (CET) program in the United States, focuses on development and licensing in novel breakthrough therapies in the medical field, as well as is committed to collaborating with relevant medical schools and research institutes in China.
The Company enters into target markets primarily through the accelerated introduction of novel breakthrough therapies from international biotechnology companies to serve patients with rare diseases and other unmet medical needs.
Winhealth has built a unique, balanced and diversified portfolio with numerous innovative rare disease and specialty products at commercial and late clinical stages, some with blockbuster potential. The company is also continuously looking to bring in more innovative therapies from the globe.